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The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for treatment of multidrug-resistant tuber-
culosis and is currently being studied as a component of novel treatment-shortening regimens for drug-susceptible andmulti-
drug-resistant tuberculosis. In a limited number of bedaquiline-treated patients reported to date,>4-fold upward shifts in be-
daquiline MIC during treatment have been attributed to non-target-based mutations in Rv0678 that putatively increase
bedaquiline efflux through theMmpS5-MmpL5 pump. These mutations also confer low-level clofazimine resistance, presum-
ably by a similar mechanism. Here, we describe a new non-target-based determinant of low-level bedaquiline and clofazimine
cross-resistance inMycobacterium tuberculosis: loss-of-function mutations in pepQ (Rv2535c), which corresponds to a putative
Xaa-Pro aminopeptidase. pepQmutants were selected in mice by treatment with clinically relevant doses of bedaquiline, with or
without clofazimine, and were shown to have bedaquiline and clofazimineMICs 4 times higher than those for the parental
H37Rv strain. Coincubation with efflux inhibitors verapamil and reserpine lowered bedaquiline MICs against both mutant and
parent strains to a level below theMIC against H37Rv in the absence of efflux pump inhibitors. However, quantitative PCR
(qPCR) revealed no significant differences in expression of Rv0678,mmpS5, ormmpL5 betweenmutant and parent strains.
Complementation of a pepQmutant with the wild-type gene restored susceptibility, indicating that loss of PepQ function is suf-
ficient for reduced susceptibility both in vitro and in mice. Although the mechanism by which mutations in pepQ confer be-
daquiline and clofazimine cross-resistance remains unclear, these results may have clinical implications and warrant further
evaluation of clinical isolates with reduced susceptibility to either drug for mutations in this gene.
Multidrug-resistant tuberculosis (MDR-TB) is a major threatto global control of tuberculosis (TB). When multidrug re-
sistance is not diagnosed, patients respond poorly to standardized
first-line regimens and additional resistance may develop. When
MDR-TB is diagnosed, current second-line regimens require pro-
longed treatment durations and are less effective, more toxic, and
far more expensive than first-line therapy (1).
The diarylquinoline drug bedaquiline (B) received acceler-
ated approval from the U.S. Food and Drug Administration
as part of combination therapy for MDR-TB when other
alternatives are not available (2). It is now being studied as a
component of novel short-course regimens for MDR as
well as drug-susceptible TB (ClinicalTrials.gov identifiers
NCT02333799, NCT02193776, NCT02589782, NCT02409290,
and NCT02454205 [https://clinicaltrials.gov/]). For new drugs
such as bedaquiline, it is essential to define and catalog the mech-
anisms conferring bacterial resistance in order to design appropri-
ate diagnostic tests (including rapid molecular tests), to better
manage the treatment of patients who fail therapy or relapse after
receiving the drug, and to conduct population level surveillance
for changes in drug susceptibility.
The principalmechanism of action of bedaquiline is inhibition
of the mycobacterial ATP synthase (3, 4). Strains selected in vitro
for resistance to bedaquiline often have mutations in atpE, which
encodes the ATP synthase subunit to which bedaquiline binds (5).
These target-based mutations cause relatively large (i.e., 10 to
128) shifts in MIC. However, it was noted that many bedaqui-
line-resistant isolates selected in vitro, typically with smaller shifts
in MIC, do not have mutations in the ATP synthase complex (5).
A new non-target-based mechanism conferring low-level be-
daquiline resistance and cross-resistance to clofazimine (C) was
recently identified among isolates from patients with delayed spu-
tum culture conversion while receiving bedaquiline forMDR-TB,
among mice treated with bedaquiline-containing combinations,
and in vitro (6, 7). Although both bedaquiline and clofazimine (7)
can select for non-target-based mutants in vitro, such mutants
have not yet been isolated frommice or patients treatedwith clofazi-
mine. The responsible mutations were found in Rv0678, which en-
codes a negative regulator of mmpL5 and mmpS5. Increased tran-
scription of these genes, which comprise a membrane transporter in
the resistance-nodulation-division (RND) family, is putatively asso-
ciated with increased efflux of bedaquiline and clofazimine.
Identification of mutations conferring cross-resistance to clo-
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fazimine and bedaquiline is important because clofazimine is a
component of some short-course regimens currently under study
for treatment ofMDR-TB (8–10) and the twodrugs are being used
together in the ongoing STREAM trial (ClinicalTrials.gov identi-
fier NCT02409290 [https://clinicaltrials.gov/]). Herein, we report
a new genetic determinant of low-level bedaquiline and clofazi-
mine cross-resistance inMycobacterium tuberculosis, conferred by
mutations in pepQ.
MATERIALS AND METHODS
Bacterial strains. M. tuberculosis H37Rv was passaged in mice, subcul-
tured in Middlebrook 7H9 (Fisher Scientific) supplemented with 10%
oleic acid-albumin-dextrose-catalase (OADC) complex (Becton-Dickin-
son) and 0.05%Tween 80 (Sigma-Aldrich), and used for aerosol infection
when the optical density at 600 nm (OD600) was approximately 1.0.
Antimicrobials. Pretomanid (Pa), moxifloxacin (M), bedaquiline,
and linezolid (L) were provided by the Global Alliance for Tuberculosis
DrugDevelopment (NewYork,NY), Bayer (Leverkusen,Germany), Jans-
sen (Beerse, Belgium), and Pfizer (Groton, CT), respectively. Rifampin
(R), isoniazid (H), pyrazinamide (Z), ethambutol (E), and clofazimine
were purchased from Fisher or Sigma. Dosing formulations were pre-
pared andmaintained as previously described (11). All drugs were admin-
istered once daily by gavage, 5 days per week.
Aerosol infection. Female BALB/c mice (Charles River, Wilmington,
MA) aged 4 to 6 weeks were infected by the aerosol route using an inha-
lation exposure system (Glas-col Inc., Terre Haute, IN). Mice were ran-
domized to treatment groups (five mice per group per time point) after
aerosol infection and were routinely sacrificed (i) on the day after infec-
tion to determine the number of CFU implanted in the lungs, (ii) on the
day of treatment initiation to determine the pretreatment CFU count, and
(iii) at selected time points during and after treatment. Quantitative cul-
tures of lung homogenates were performed in parallel on selective 7H11
agar with and without 0.4% activated charcoal to reduce drug carryover
effects, as previously described (11). All procedures involving animals
were approved by the Animal Care and Use Committee of Johns Hopkins
University.
Efficacy of combinations containingbedaquiline and clofazimine in
murine models of TB. Beginning 14 days after high-dose aerosol infec-
tion, as previously described (12), BALB/c mice received no treatment
(negative controls) or treatment with the first-line regimen of R-H-Z
(positive controls) or one of the following test regimens: bedaquiline (25
mg/kg [of body weight]) alone, the two-drug combination of bedaquiline
plus clofazimine (20 mg/kg), or three-drug combinations of bedaquiline
plus clofazimine plus one of the following: rifampin (10mg/kg), isoniazid
(10 mg/kg), pyrazinamide (150 mg/kg), ethambutol (100 mg/kg), moxi-
floxacin (100mg/kg), pretomanid (50mg/kg), and linezolid (100mg/kg).
Lung CFU counts were determined for all treatment groups after 4 weeks
of treatment and, for mice receiving bedaquiline alone and bedaquiline
plus clofazimine, also after 6 and 8 weeks of treatment.
MIC determination. Determination of bedaquiline and clofazimine
MICs and the proportion of drug-resistant mutants was performed using
the agar proportionmethod. Serial dilutions of lung homogenates, colony
suspensions, or a broth culture were inoculated in 500-l aliquots onto
7H11 plates with and without the desired drug. MICs were determined
using doubling bedaquiline and clofazimine concentrations ranging from
0.003 to 0.25 g/ml and 0.06 to 2 g/ml, respectively. The MIC was de-
fined as the lowest drug concentration inhibiting at least 99% of the
growth observed on drug-free control plates. To investigate the effect of
efflux pump inhibitors on the susceptibility of the strains, the MIC of
bedaquiline was also determined using the broth macrodilution method.
Doubling concentrations of bedaquiline from 0.007 to 1 g/ml were
tested in the presence or absence of 40 g/ml of verapamil or 3 g/ml of
reserpine. Briefly, tubes containing in 2.5 ml of 7H9 broth plus OADC
with the above-mentioned concentrations of bedaquiline were inoculated
with 105 CFU of log-phase culture of H37Rv or the B5 mutant. The MIC
was defined as the lowest concentration that prevented visible growth
after 14 days of incubation at 37°C. Controls with and without efflux
inhibitors and bedaquiline were included for each test. The experiment
was performed twice.
DNA sequencing. Genomic DNA from the parental wild-type strain
and resistant mutants was extracted by using the cetyltrimethylammo-
nium bromide (CTAB) protocol (13) and sonicated (Covaris, Inc.). The
DNA library was constructed by using a genomic DNA sample prepara-
tion kit (Illumina, Inc.). The samples were sequenced on an Illumina
Genome Analyzer II, which was operated in paired-end mode, collecting
pairs of 51-bp reads from opposite ends of 250- to 350-bp fragments.
Image analysis and base-calling were done by using the Illumina GA Pipe-
line software (v0.3). Genome assembly was performed by a comparative
assembly method using software developed in-house. Briefly, reads were
aligned to the genome of H37Rv as a reference sequence, and then local
contig building was used to identify insertions and deletions (14). Muta-
tions in pepQ (Rv2535c) were confirmed by PCR amplification using spe-
cific primers (see Table S1 in the supplemental material).
In vivo confirmation of low-level cross-resistance to bedaquiline
and clofazimine. BALB/c mice were infected with either the H37Rv par-
ent strain or an isogenic strain (B5) with a nonsynonymous pepQ muta-
tion and randomized to receive no treatment, isoniazid (10mg/kg) alone,
bedaquiline (12.5, 25, or 50 mg/kg) alone, clofazimine (20 mg/kg) alone,
or bedaquiline at 25mg/kg plus clofazimine. Treatment began 4 days after
infection and was administered for 4 weeks for all groups, except the
groups receiving bedaquiline at 25mg/kg, which received 8weeks of treat-
ment.
Complementation studies to confirm that a pepQmutation is suffi-
cient for bedaquiline and clofazimine cross-resistance. The B5 strain
was complemented with pDT-Rv2535c (see Fig. S1 in the supplemental
material) containing the wild-type pepQ gene fromH37Rv. Complemen-
tation was confirmed by showing a loss of susceptibility to hygromycin
and PCR for presence of the hygromycin resistance gene. Bedaquiline and
clofazimine MICs were determined in vitro. Following aerosol infection
with the H37Rv parent strain, the B5 mutant, or the B5::pepQ comple-
mented strain, BALB/c mice were randomized to receive no treatment,
isoniazid at 10 mg/kg, bedaquiline at 25 mg/kg, or clofazimine at 20 mg/
kg. Treatment began 3 days after infection and continued for 4 weeks
before mice were sacrificed to determine lung CFU counts.
Expression analysis of mmpS5, mmpL5, and Rv0678. The H37Rv
parent strain and the B5 mutant were grown to mid-log phase (OD600
0.6) in 7H9 broth, and cells were pelleted by centrifugation. RNA was
extracted by bead beating in TRIzol and column purified according to the
manufacturer’s instructions (Qiagen, Valencia, CA). RNA was reverse
transcribed using the iScript Reverse Transcription Supermix (Bio-Rad,
Hercules, CA). Real-time PCRwas performed with iQ SYBR green super-
mix on an iCycler (Bio-Rad, Hercules, CA) using primers specific for
Rv0676c, Rv0677c, and Rv0678 and 16S rRNA (see Table S1 in the supple-
mental material). All experiments were performed in biological and tech-
nical triplicates. Cycle threshold (CT) values were normalized against 16S
rRNA expression, and fold change was calculated by the2CT method
(15).
Expression, purification, and activity assays of PepQ. The entire
coding region of Rv2535c was cloned into the pET28b expression vector
(Novagen) containing an in-frame N-terminal 6 His tag with the to-
bacco etch virus (TEV) cleavage site using the NdeI and HindIII restric-
tion sites. The plasmid was transformed into Escherichia coli BL21(DE3)
cells for expression of Rv2535c. Cells containing the plasmid were grown
at 37°C for 7 h in LB medium with 50 g/ml of kanamycin followed by
induction with 1 mM isopropyl--D-thiogalactopyranoside (IPTG) and
grown overnight at 18°C. The cells were lysed via an M-100P microfluid-
izer (Microfluidics, Worcestershire, United Kingdom) in lysis buffer (50
mMTris [pH 7.5], 500mMNaCl, 5% glycerol, DNase, and 2mMMgCl2)
and centrifuged at 15,000 rpm for 1 h. The supernatant was chromato-
graphed over a His tag affinity column (GE Healthcare) charged with Ni.
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The protein was eluted with 0 to 300 mM imidazole gradient, and the 6
His tag was cleaved using the tobacco etch virus protease. The final puri-
fication step was gel filtration chromatography on the standardized s200
Superdex (GE Healthcare) column. The PepQ protein was eluted in two
peaks: a large-molecular-mass aggregate that came out near the void vol-
ume, followed by a distinct peak with calculated molecular mass corre-
sponding to a tetramer (160 kDa). Formation of this tetramer is consis-
tent with other related proteins, e.g., the protein with PDB code 3Q6D.
The protein was	95% pure, as observed by SDS-PAGE and was concen-
trated to 7.5mg/ml, flash frozen, and stored in dialysis buffer (50mMTris
[pH 7], 50mMNaCl, 5% glycerol, 1mMdithiothreitol [DTT]) at80°C.
The purified recombinant PepQ tetramer in 50mMTris (pH7)was tested
for both creatinase activity using the creatinase assay kit (Sigma) and
endopeptidase activity using commercially available fluorescent peptides.
As the peptides were all labeled with a p-nitroanilide group, the assay
monitored for a shift in absorbance at 410 nm, resulting from the cleaved
product.
Statistical analysis. CFU counts were log10 transformed before anal-
ysis. Group means for experimental treatment groups were compared
with that of the standard treatment control by one-way analysis of vari-
ance (ANOVA) with Dunnett’s posttest to adjust for multiple compari-
sons. All analyses were performed with GraphPad Prism v.4.01 (Graph-
Pad, San Diego, CA).
RESULTS
Bedaquiline and clofazimine have additive activity against M.
tuberculosis inmicebut select for cross-resistantmutants.Using
a well-established high-dose aerosolmodel of TB inmice, we eval-
uated the activity of novel drug combinations containing be-
daquiline and clofazimine (Fig. 1). Consistent with prior observa-
tions (3, 11, 16), treatment with the standard first-line R-H-Z
regimen reduced the mean lung CFU count by 2.46 log10 over the
first 4 weeks and treatment with bedaquiline alone reduced the
lung CFU counts by an additional 1.08 log10. The addition of
pyrazinamide and clofazimine each significantly increased the ac-
tivity of bedaquiline (P 
 0.001), whereas the addition of preto-
manid had antagonistic effects (P
 0.05). The addition of rifam-
pin, isoniazid, ethambutol, or moxifloxacin did not significantly
affect the activity of the bedaquiline-clofazimine combination,
whereas addition of pyrazinamide significantly increased the ac-
tivity (P
 0.001) and addition of linezolid or pretomanid reduced
the activity (P 
 0.05). After 8 weeks of treatment, 2 of 5 mice
receiving bedaquiline alone hadmore than 3 log CFU in the lungs,
while the mean log CFU count was 0.98 0.53 in the remaining 3
mice. Likewise, 3 of 5 mice receiving bedaquiline plus clofazimine
had a mean log CFU count of 2.12 0.69, while the remaining 2
mice were culture negative, as were all 5 mice treated for just 6
weeks (Fig. 1, inset). Unlike those from mice with lower CFU
counts at week 8, the isolates from the lungs of mice with higher
CFU counts grew equally well on 7H11 agar with and without
activated charcoal, indicating that their growth was not impaired
by bedaquiline or clofazimine carried over in the lung homoge-
nates.
While bedaquiline and clofazimine MICs for the wild-type
H37Rv parent strain were 0.03 and 0.25g/ml, respectively,MICs
for the isolates from the 2 mice treated with bedaquiline alone for
8 weeks (named B4 and B5) and the 3 mice treated with bedaqui-
line plus clofazimine for 8 weeks (named BC2, BC3, and BC4)
with high, outlying lung CFU counts were 0.12 to 0.25 and 0.5 to 1
g/ml, respectively, indicating that treatment with bedaquiline,
with or without clofazimine, selected for strains with reduced sus-
ceptibility to both drugs.
Isolates with bedaquiline and clofazimine cross-resistance
harbored mutations in pepQ. Duplicate samples of genomic
DNA from four cross-resistant strains isolated in the first mouse
experiment (i.e., B5, BC2, BC3, and BC4) were sequenced on an
Illumina GenomeAnalyzer IIx in paired-end mode using a read
length of 51 bp. The mean depth of coverage ranged from 118 to
161 (number of reads covering each site, averaged over the
whole genome), and the completion was	99% (fraction of sites
in 4.4-Mb genome covered by at least 1 read; sites lacking coverage
were primarily restricted to PPE and PE_PGRS genes, due to very
high GC contents). The parental strain used in these experiments
(H37RvJH) was also sequenced, to identify any differences from
the public reference genome sequence for H37Rv (17). Compared
to the sequence of the parental strain, only one mutation was
observed in each strain (Table 1). All 4 strains had a mutation in
pepQ (Rv2535c), which encodes a putative cytoplasmic peptidase.
The mutations observed included 2 frameshift mutations (C in
Arg271 and C in Ala14) in mice treated with the bedaquiline-
clofazimine combination, as well as a nonsynonymous single nu-
cleotide polymorphism causing a Leu44Pro mutation, obtained
from a mouse treated with bedaquiline alone. All mutations were
confirmed by PCR amplification and sequencing.
TABLE 1 Sequencing results for the resistant strainsa
Mouse no. Treatment Coverage % completion Mutation
B5 B 142.1 99.25 pepQ: L44P
BC2 B C 118.4 99.20 pepQ:C in
Ala14
BC3 B C 154.3 99.43 pepQ:C in
Ala14
BC4 B C 161.1 99.14 pepQ:C in
Arg271
a For all strains, the MIC of bedaquiline (B) was 0.12 g/ml and that of clofazimine (C)
was 0.5 to 1 g/ml.
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FIG 1 Mean lung log10 CFU counts (SD) after 4 and 8 weeks of treatment
with bedaquiline- and clofazimine-containing regimens. Themain graph does
not include results from mice in which bedaquiline and clofazimine cross-
resistant mutants were selected after 8 weeks of treatment: 2 and 3 mice from
the B and BC groups with mean lung CFU counts of 3.22 0.16 and 2.12
0.69 log10, respectively (inset). The CFU counts at the time of treatment initi-
ation are indicated at day 0. Abbreviations: R, rifampin; H, isoniazid; Z, pyr-
azinamide; B, bedaquiline; C, clofazimine; L, linezolid; Pa, pretomanid; E,
ethambutol; M, moxifloxacin.
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ApepQmutant is virulent and less susceptible tobedaquiline
and clofazimine in amurine TBmodel. Because transposonmu-
tagenesis experiments have suggested that inactivation of pepQ
may reduce the fitness of M. tuberculosis (18), and because the
pepQ mutants displayed only low-level resistance to bedaquiline
and clofazimine in vitro, we sought to confirm their virulence and
reduced susceptibility in vivo. We compared the parental H37Rv
strain and the B5 mutant on the basis of their abilities to multiply
in untreated BALB/c mice and their susceptibilities to treatment
with isoniazid (positive control), bedaquiline, and/or clofazimine.
The aerosol infectious dose was approximately 1 log10 higher for
the parent strain than for the B5 mutant (Fig. 2). By 4 weeks
postinfection, untreated (UT) control mice infected with H37Rv
had died, and therefore, none were available for CFU counts (al-
though lung CFU counts are typically	8 log10, or approximately
4 log10 higher than baseline, at the time of death). Untreated mice
infected with B5 did not die within 4 weeks of infection because
the infectious dose was not high enough. However, the approxi-
mately 4-log10 increase in lung CFU counts over this period is
evidence that the strain multiplies more or less normally in mice.
The treatment with isoniazid (positive control) was at least as
bactericidal against the B5 strain as against H37Rv, reducing the
lung CFU counts by more than 1 log10 in both strains. Dose-
dependent activity of bedaquiline was observed against both
strains. However, while bedaquiline at 12.5 mg/kg was bacterio-
static and 50 mg/kg reduced the lung CFU counts by more than 2
log10 against H37Rv, even 50 mg/kg of bedaquiline did not fully
inhibitmultiplication of the B5mutant but rather allowed a nearly
2-log10 increase in CFU counts. Clofazimine enabled growth of
both strains in this acute infection model, as previously observed
(19), but was more effective against the H37Rv strain than against
the B5 mutant.
Complementation of pepQ restores susceptibility to be-
daquiline and clofazimine.Complementation of the B5 and BC2
strains with the wild-type pepQ gene from H37Rv restored the
susceptibility of the strains to bedaquiline, as confirmed by the
MIC of 0.03 g/ml, which was no different from that for the pa-
rental H37Rv control. Following this, 3 groups of mice were in-
fected with H37Rv, the B5 strain, or the B5::pepQ strain and ini-
tiated on treatment with isoniazid at 10 mg/kg, bedaquiline at 25
mg/kg, or clofazimine at 20 mg/kg 4 days later. In untreated mice,
lung CFU counts increased by approximately 4 log10 over the sub-
sequent 4 weeks (Fig. 3) and were accompanied by visible lung
lesions (see Fig. S2 in the supplemental material). Isoniazid was
bactericidal, with the greatest effect against the B5 strain, and pre-
vented the formation of lung lesions. Like isoniazid, bedaquiline
reduced the mean lung CFU counts by 0.5 to 1 log10 CFU against
H37Rv and the B5::pepQ strain, and it did prevent formation of
macroscopic lung lesions inmice infected with the B5mutant (see
Fig. S2 in the supplemental material). However, bedaquiline al-
lowed a	1-log10 increase in mean CFU counts of the B5 mutant.
Clofazimine, which has a relatively poor activity in this acute in-
fectionmodel when given alone (19), allowedmultiplication of all
strains but significantly reduced the multiplication of the H37Rv
(P
 0.05) and B5::pepQ (P
 0.05) strains but not the B5 strain
(P	 0.05) compared to findings with no treatment. In addition,
clofazimine prevented formation of lung lesions in mice infected
withH37Rv and the B5::pepQ complemented strain but not the B5
strain (see Fig. S2 in the supplemental material). These results
clearly demonstrate that complementation with the wild-type
pepQ gene was sufficient to restore susceptibility to bedaquiline
and clofazimine in the B5mutant and thus confirm that the loss of
PepQ function is sufficient for low-level resistance to bedaquiline
and clofazimine.
Structural analysis of M. tuberculosis pepQ product. pepQ
encodes a 372-amino-acid (aa) protein that has two domains: an
100-aa N-terminal alpha/beta domain and an 250-aa C-ter-
minal peptidase domain (Fig. 4). Based on homology to Ypdf in E.
coli (e.g., 37% amino acid identity over 363 residues),M. tubercu-
losis pepQ is predicted to encode a proline-specific aminopepti-
dase (prolidase), active on substrates with Xaa1-Pro2 at the amino
terminus. The C-terminal domain of YpdF houses the catalytic
activity and is homologous to the E. colimethionine aminopepti-
dase (MetAP; 29% amino acid identity) (20). However, MetAP
FIG 2 Mean lung log10 CFU counts (SD) (A and B) and change in CFU counts (week 4 day 0) (C and D) after 4 weeks of treatment in mice infected with
the parental H37Rv strain (A and C) or the B5 mutant (B and D). CFU counts were not determined for untreated mice infected with the parental strain, which
required euthanasia prior to the predetermined endpoint. Abbreviations: UT, untreated; H, isoniazid (10 mg/kg); C, clofazimine (20 mg/kg); B, bedaquiline
(12.5, 25, or 50 mg/kg).
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lacks the N-terminal domain. In enzyme assays, YpdF was found
to have weak activity on substrates with an N-terminal methio-
nine (Met-Xaa) if the second amino acid is alanine, proline, or
serine and higher activity for other substrates with a proline in the
second position (Xaa-Pro) (21). In E. coli, YpdF is encoded in an
operon with YpdE, which is a methionine aminopeptidase. YpdF
and YpdE are proposed to work in concert to degrade proteins,
with YpdE removing amino acids from the N terminus until a
proline is encountered in the second position and YpdF removing
the block (21). TheM. tuberculosis pepQ product also has homol-
ogy (30% amino acid identity) to other E. coli proline amino-
peptidases, the pepP and pepQ products, which have both the cat-
alytic C-terminal domain and a noncatalytic N-terminal domain
that plays a role in oligomerization and substrate specificity. The
pepP product and similar aminopeptidase P enzymes (EC
3.4.11.9) may preferentially hydrolyze the Xaa-Pro bond at the
terminus of larger oligopeptides (but also dipeptides) and can
discriminate the 3rd and 4th residues in their catalytic specificity.
Proline aminopeptidases have a 2-domain architecture similar
to that of creatinases (which catalyze a similar reaction, hydrolysis
of creatine into sarcosine and urea), although the peptidase activ-
ity of the former is metal ion dependent and they bind cations in
the active site (20), whereas creatinase activity does not require
metal ions (22, 23). The mutations selected by treatment with
bedaquiline with or without clofazimine in mice occurred in both
domains. The frameshift mutation in Ala14 and the nonsynony-
mous mutation L44P occur in the N-terminal domain, and the
frameshift mutation in Arg271 occurs in the catalytic domain.
Figure 4 illustrates where thesemutations fall in the domain struc-
ture of the pepQ product. To better understand the role of these
mutations, we used Phyre2 (24) to build a homologymodel of the
three-dimensional (3D) atomic structure of the pepQ product.
Phyre2 detected the greatest homology to a proline aminopepti-
dase from Bacillus anthracis (PDB code 3Q6D; 39% amino acid
identity; deposited by Midwest Center for Structural Genomics).
Phyre2 created a hidden Markov model based on a PSI-BLAST
alignment of closely related sequences and used it to optimally
thread theM. tuberculosis pepQproduct amino acid sequence onto
the 3Q6D structure as a template, followed by loop optimization
and energyminimization (24). The active site can be inferred to be
in a pocket in theC-terminal domain containing aCa2metal ion,
in the same position as the dinuclear divalent cation sites in pepP
(1a16) and MetAP (3mat), which is involved in catalyzing the
cleavage of the scissile peptide bond. The cations are coordinated
byD221, D232, E339, E325, andHis296 (M. tuberculosis pepQ), all
perfectly conserved in all of these structures. Based on the homol-
ogy model, Leu44 ofM. tuberculosis pepQ appears to be buried in
the core of the N-terminal domain (on a beta strand that shows a
FIG 3 Mean lung log10 CFU counts (SD) (A to C) and change in lung CFU counts (week 4 day 0) (D to F) after 4 weeks of treatment in mice infected with
the parental H37Rv strain (A and D), the B5 mutant (B and E), or the complemented B5::pepQ strain (C and F). Abbreviations: UT, untreated; H, isoniazid (10
mg/kg); C, clofazimine (20 mg/kg); B, bedaquiline (25 mg/kg).
FIG 4 Locations of mutations and domains in pepQ.
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high level of conservation with E. coli pepP and both prokaryotic
and eukaryotic prolidases [25]), not in close proximity to the ac-
tive site. Thus, L44P is likely a structure-destabilizingmutation, as
is the frameshift mutation in Ala14. A frameshift in Arg271 would
truncate half the C-terminal domain (splitting the pseudosym-
metric alpha/beta “pita bread” fold in half and destroying the ac-
tive site).
The PepQ model can be superimposed with the crystal struc-
ture of the E. coli MetAP protein (3mat), which was complexed
with a peptide inhibitor (bestatin analog). The mechanism and
specificity determinants of E. coli MetAP have been well charac-
terized (20). MetAP has a dinuclear cation site (2 Co2) in the
same location as in 3Q6D. The N-terminal residue of the peptide
inhibitor of MetAP binds in a P1 pocket, and the second residue
binds in a P2 pocket, with the polar backbone atoms of the scissile
bond between them coordinating the cations. The residues of M.
tuberculosis PepQ lining the P1 part of the pocket are considerably
different than MetAP. For example, F190 is replaced with Cys in
MetAP, and I302 is replaced with F. This could potentially explain
differences in specificity for the N-terminal residue between pro-
lidases andmethionine aminopeptidases (26).While the inhibitor
in the 3mat structure mimics Met1-Ala2, YpdF would be expected
to bind Xaa1-Pro2 as a prolidase. The putative position of the P2
pocket can also be inferred by superimposing the crystal structure
of E. coli PepP in complex with the inhibitor Pro-Leu (PDB code
1a16), which putatively mimics the 2nd and 3rd residues of a
peptide substrate. In both MetAP and the pepP product, the P2
pocket is adjacent to residue His-204. While the homology be-
tweenM. tuberculosis pepQ and E. coli pepP is relatively low (31%
amino acid identity), nearly every residue in the vicinity of the
active site was either identical or highly conserved. The residues
lining the P1 pocket are F190 (Y), I302 (V),H303, T341 (D), T232,
and V398 (L), with residues of the E. coli pepP product shown in
parentheses. The residues lining P2 are T234, I193, R337, H204,
P203 (L), andH292 (Fig. 5). Thus, we expectM. tuberculosis PepQ
to be able to coordinatemetal ions similarly to E. coli PepP and the
specificity of M. tuberculosis PepQ to be very similar to that of E.
coli PepP, i.e., to correspond to a proline aminopeptidase (Xaa-
Pro).
Enzymatic characterizationofM. tuberculosisPepQ.Recom-
binant purifiedM. tuberculosis pepQ product exhibited no creati-
nase activity (data not shown). Of the 6 proline-containing pep-
tide substrates tested, only Arg-Pro-p-nitroanilide showed
modest cleavage activity. Several substrates with an N-terminal
methionine were also tested. However, none of these showed
cleavage, suggesting that the pepQ product is not a methionine
aminopeptidase.
Mass spectrometry showed that recombinant M. tuberculosis
pepQproduct does not bind to ormodify the structure of bedaqui-
line or clofazimine. Overexpression of M. tuberculosis pepQ in
FIG 5 Multiple amino acid sequence alignment for the products ofM. tuberculosis pepQ, Lactococcus lactis pepP, and E. coli pepP, constructed using ClustalW.
Residues coordinating the Mn2 ions are shown in red. Asterisks indicate positions which have a single, fully conserved residue. Colons indicate conservation
between groups of strongly similar properties, scoring 	0.5 in the Gonnet PAM 250 matrix. Periods indicate conservation between groups of weakly similar
properties, scoring0.5 in the Gonnet PAM 250 matrix.
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Mycobacterium smegmatis did not significantly alter the MIC of
bedaquiline or clofazimine. This is not surprising, as the muta-
tions presumably result in loss of function. Taken together, these
results suggest that PepQ is not a target or activating enzyme for
either drug.
Resistance mediated by pepQ mutation may be associated
with increased drug efflux, but this is not due to upregulation of
mmpL5 and mmpS5 expression. Addition of verapamil and re-
serpine reduced the MIC against the H37Rv parent strain from
0.03 to 0.007 g/ml and 0.015 to 0.03 g/ml, respectively. Both
efflux inhibitors reduced the MIC of both the B5 mutant and the
H37Rv parent to the same level that was below theMIC against the
parent strain in the absence of the efflux inhibitor, indicating a
possible role of one or more efflux pumps in the mechanism of
low-level bedaquiline resistance mediated by loss-of-function
mutations in pepQ (see Table S2 in the supplemental material).
Further, quantitative PCR (qPCR) for the genes involved in the
efflux-mediated resistance reported in previous studies did not
show any significant fold change in transcription levels (see Table
S3 in the supplemental material).
DISCUSSION
Bedaquiline is a promising new drug for the treatment of TB. Its
limited clinical usage to date has provided little opportunity to
select for drug-resistant mutants or to assess the impact of such
mutants on treatment outcomes. In vitro-selected target-based
mutations in atpE confer high-level resistance to bedaquiline (e.g.,
16 to 128 increase in MIC) (5, 6). However, to our knowledge,
no atpE mutant has been isolated from a patient treated with be-
daquiline. On the other hand, nontarget mutations in Rv0678
conferring low-level resistance to bedaquiline and clofazimine
were recently described for sputum isolates with at least 4-fold
increases in bedaquiline MIC after treatment including bedaqui-
line (6). More recently, Rv0678 mutants were identified in the
sputa of bothMDR-TB and drug-susceptible TB patients that had
not received bedaquiline or clofazimine (27). Although these
Rv0678 mutations cause relatively small (2 to 8) increases in
bedaquiline and clofazimine MICs compared to mutations in
atpE, their selection during combination therapy in TB patients
and in mice is a cause of concern (6). In mice, Rv0678 resistant
mutants may be selected with 8 weeks of bedaquiline mono-
therapy (D. Almeida, unpublished observation) but emerge only
late in the course of combination therapy and are eventually
cleared, presumably by the action of companion agents (6). Clin-
ically, thesemutants emerged almost entirely among patients with
pre-XDR- and XDR-TB (6), but their isolation has not clearly
been associated with poorer clinical outcomes among patients re-
ceiving bedaquiline with more effective companion agents (28).
These results underscore the importance of appropriate combina-
tion therapy and adherence and the risk of premature discontin-
uation of therapy.
The present study provides the first evidence of nontarget mu-
tations in pepQ conferring low-level resistance to bedaquiline and
cross-resistance to clofazimine. Zhang et al. (29) recently reported
in vitro selection of a pepQmutant inM. tuberculosis with clofazi-
mine. However, they did not report the results of direct suscepti-
bility testing with clofazimine or bedaquiline or confirm the caus-
ative role of pepQ mutation in clofazimine resistance. Like
mutations in Rv0678 (6), the observed pepQ mutations produce
modest increases (up to 4-fold) in bedaquiline and clofazimine
MICs and reduce the efficacy of bedaquiline and clofazimine in
vivo. However, these mutations did not result in complete resis-
tance to these drugs, as increasing doses of bedaquiline and, to a
lesser extent, combining bedaquiline and clofazimine were asso-
ciated with a greater antituberculosis effect. These data and the
additive bactericidal and sterilizing effects of bedaquiline and clo-
fazimine against drug-susceptible bacilli (30) indicate that despite
the presence of two shared resistance mechanisms, the combined
use of clofazimine and bedaquiline may be advantageous. How-
ever, these two drugs will not protect each other against the emer-
gence of resistance, and it is therefore important to use them in com-
bination only if they are protected from emergence of resistance by
additional antibiotics that are not substrates of the same efflux
pumps. BothRv0678 and pepQmutants are selected and able to grow
inmice treatedwithbedaquiline, despiteplasmabedaquiline concen-
trations exceeding theMICagainst these resistant organisms (11, 31).
This may be due to the high protein binding of bedaquiline, which
results in free drug concentrations below theMIC at the site of infec-
tion. Rv0678 mutants and pepQ mutants may be selected preferen-
tially overatpEmutants in vivoduringbedaquiline treatmentbecause
they strike the right balance between reduced susceptibility to be-
daquiline andmaintenance of fitness.
Our findings may have implications for breakpoint selection
for bedaquiline susceptibility testing. Although the bedaquiline
MIC against the pepQ mutants is below the provisional suscepti-
bility breakpoint of 0.5 g/ml proposed by EUCAST (32), mono-
therapy with clinically relevant bedaquiline doses inmice infected
with a pepQ mutant had limited efficacy. These findings and the
limited clinical data available to date warrant careful monitoring
of bedaquilineMICs and treatment outcomes and further consid-
eration whether a lower breakpoint would better predict patient
response to bedaquiline treatment. Polymorphisms in Rv0678
have recently been observed among isolates from patients that
have not received bedaquiline or clofazimine and are not always
associated with bedaquiline MICs that exceed the provisional
breakpoint (27), and it remains unclear whether suchRv0678mu-
tations are associated with poorer clinical outcomes among pa-
tients receiving bedaquiline-containing regimens (6, 28). Thus,
the clinical impact of the small shift in MIC conferred by pepQ
mutations remains to be determined. Further surveillance is re-
quired to identifyRv0678 and pepQmutants and to correlate their
presence withMICs and clinical outcomes among patients receiv-
ing therapy that includes one or both drugs.
It is interesting that single nucleotide polymorphisms in pepQ
were occasionally observed in clinical isolates that we have se-
quenced. In particular, pepQ::Ser66Pro was observed in two
XDR-TB isolates (X16 and X23; Beijing strain family) and an
MDR-TB isolate (R1792; LCC strain family) from the Western
Cape of South Africa, all isolated prior to the introduction of
bedaquiline (33). No other strains were observed to have muta-
tions in pepQ among over 50 clinical isolates from South Africa
and South America. It is possible that use of clofazimine to treat
MDR-TB in this region could have contributed to selective ampli-
fication of these mutants. However, this seems unlikely given the
limited usage of clofazimine in South Africa during the period in
which such selection would have occurred. The clinical isolates
with polymorphisms in pepQ were not available for drug suscep-
tibility testing. However, the presence of Rv0678 and pepQmuta-
tions in isolates from patients naive to bedaquiline and clofazi-
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mine raises the possibility that they may also be selected by other
drugs used to treat TB or other infections.
What is the function of PepQ inM. tuberculosis, and howmight
loss of function result in reduced susceptibility to bedaquiline and
clofazimine? While further characterization of the enzymatic ac-
tivity of PepQ is clearly required before drawing conclusions, the
genomic and structural characterization described here suggests
that the pepQ product is a proline-specific aminopeptidase and
ortholog of the pepP product in E. coli and Lactococcus lactis and
PapA (YqhT) in Bacillus subtilis (34). This is supported by homol-
ogy in both genetic sequence and predicted protein structure. Al-
though the DNA sequence homology is not particularly high,
there is a high degree of conservation of amino acids in the pre-
dicted active site, including strict conservation of metal-binding
residues between PepQ and PepP from both E. coli and L. lactis.
Moreover, each of these orthologous genes is situated next to and
coexpressed with elongation factor P (EF-P; Rv2534c), one of the
few universally conserved elongation factors (34). Conserved ho-
mologs also exist in other pathogenic mycobacteria (M. bovis,M.
leprae, andM. paratuberculosis) (35).
Proline-specific aminopeptidases are among only 80 enzymes
conserved in the 3 major kingdoms of life (36). Such high conser-
vation may stem from the exceptional conformational rigidity
that proline residues introduce into peptide chains, which pres-
ents challenges to proteolytic enzyme systems. For example, in E.
coli, the essentialmethionine aminopeptidase (PepM) responsible
for cotranslational N-terminal methionine excision readily liber-
ates the N-terminal methionine when proline or an amino acid
with a similarly small side chain occupies the penultimate posi-
tion. However, a proline in the third position inhibits PepM ac-
tivity (37, 38), making PepP required for efficient N-terminal me-
thionine excision in such cases (39).
The conformational constraints of polyproline motifs also
present challenges during ribosomal peptide synthesis by stalling
translation. As EF-P is required to prevent such stalling and pro-
mote efficient translation of polyproline-containing peptides (40,
41), the genomic organization of a putative proline-specific ami-
nopeptidase like the pepQ product with EF-P is likely no coinci-
dence. Work with Gram-negative enteric pathogens has revealed
that proteins with EF-P target motifs (and hence dependent on
EF-P for optimal translation) are enriched formetabolic enzymes,
membrane-associated proteins, transporters, and two-compo-
nent regulatory systems (42). The same appears to be true for M.
tuberculosis. This system may have evolved for rapid remodeling
of the cellular proteome in response to changing environmental
conditions, such as carbon source (43, 44). The highly conserved
organization of genes for proline-specific aminopeptidases and
EF-P in bacteria thus supports a potential role for pepQ in regu-
latingmaturation and/or turnover of specific proteins in amanner
that is sensitive to the metabolic status ofM. tuberculosis.
Proline-specific aminopeptidases also have important roles in
the utilization of exogenous and endogenous proteins as sources
of essential amino acids useful for protein synthesis, energy pro-
duction, osmoprotection, and recycling of reduced cofactors. Pro-
line itself is increasingly recognized as having a critical role in
energymetabolism, redox control, and bacterial virulence (45). In
early transposon mutagenesis studies (18), disruptions of pepQ
were observed to cause a growth defect (thus pepQ is neither ab-
solutely essential nor nonessential in vitro). More recent high-
resolution transposon mutagenesis studies suggest that pepQ is
conditionally essential when grown on glycerol as a carbon source
but not essential when grown on cholesterol (P value 
 0.01 for
comparison of transposon insertion counts) (46). This is interest-
ing given recent evidence linking mycobacterial proline catabo-
lism to protection from the toxic effects of methylglyoxal pro-
duced during growth on glycerol (47). If mutation of pepQ
reduces intracellular availability of proline, this might increase
susceptibility to methylglyoxal and reduce growth on glycerol.
The mechanism by which pepQmutations result in reduced
susceptibility to bedaquiline and clofazimine is unclear.
Rv0678 mutations appear to confer cross-resistance to be-
daquiline and clofazimine via derepression of mmpL5-mmpS5
(Rv0676c-Rv0677c), which encode an RND transporter capable
of exporting bedaquiline and clofazimine (6, 7). Reversion of be-
daquiline susceptibility of a pepQ mutant to that of its wild-type
parent in the presence of efflux pump inhibitors suggests that drug
efflux is involved in themechanism of resistance. However, unlike
the mutations in Rv0678, the mutation in pepQ is not associated
with overexpression of mmpL5 or mmpS5. One possibility is that
pepQ mutations increase efflux through this transporter by a dif-
ferent means, such as preventing degradation of MmpL5, which
contains a Val-Pro-Pro stretch near the amino terminus.
In conclusion, we demonstrate that loss-of-function muta-
tions in pepQ confer reduced susceptibility to bedaquiline and
clofazimine.While the shift in susceptibility is relatively small, it is
of a magnitude similar to those of mutations in Rv0678 that have
been selected in patients and mice receiving combination therapy
including bedaquiline. Therefore, these results should provide the
impetus to include pepQ in the genetic analysis of bedaquiline-
and clofazimine-resistant strains identified during clinical usage.
Further study of the biological function of pepQ inM. tuberculosis
and themechanism bywhich pepQmutations confer reduced sus-
ceptibility is clearly warranted.
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